Trial primary completion date • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2) • DDX3X (DEAD-Box Helicase 3 X-Linked)
|
TET2 mutation • PTPN2 mutation
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor) • vincristine • prednisone